Skip to content
Study details
Enrolling now

Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia

Vishwajit Nimgaonkar, MD PhD
NCT IDNCT03794076ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1/2

Target enrollment

160

Study length

about 7.3 years

Ages

18–65

Locations

1 site in PA

What this study is about

Researchers are testing whether cromoglicate, a treatment, can help people with schizophrenia. The trial will last 2647 days and involve approximately 160 participants. Participants will be randomly assigned to receive either cromoglicate or a placebo.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Cromoglycate
  • 2.Take Placebo

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Primary: Improvement in positive symptoms

Secondary: Cognition, Negative Symptoms, Quality of Life Scale (QOL), Total Symptoms

Body systems

Psychiatry / Mental Health